The results from the EMPORER‐Preserved trial,8 and the post‐hoc analysis of the TOPCAT trial34 raise the opportunity to learn how sodium‐glucose cotransporter 2 (SGLT2) inhibitors and aldosterone antagonists could influence these common mechanisms and impact on the deleterious AF/HFpEF relationship. The gene discussed is SLC5A2; the disease is atrial fibrillation.